The Utah Jazz's Derek Fisher finds himself in a whole new ballgame lately as he helps his 10-month-old daughter, Tatum, fight for her life.

Tatum was diagnosed last week with retinoblastoma, a cancerous tumor in her left eye. Fisher, who was excused from his team to begin dealing with his daughter's illness, flew his family -- his wife Candace, Tatum, and Tatum's twin brother Drew -- to New York on Monday to see a specialist.

Fisher and his wife must decide on a course of treatment for their daughter. Their options are removal of the eye or a combination of surgery and chemotherapy. Their most pressing goal is to save Tatum's life. They also want to save her eye. And they think in her case, she should be able to keep her eye.

Patients diagnosed with retinoblastoma have a greater chance than the general public of developing soft-tissue sarcomas over their lifetime, says an article recently published in the Journal of the National Cancer Institute.

Retinoblastoma is a rare cancer that originates in the eye. Treatment for retinoblastoma often includes radiation therapy and may also include chemotherapy and surgical removal of the eye. There has been some concern that radiation therapy increases the risk of developing cancer in tissues within the radiation field.

The National Cancer Institute recently conducted a study to evaluate potential associates between patients diagnosed with retinoblastoma and the rate of soft-tissue sarcomas following treatment.

The study included 963 patients treated and diagnosed with hereditary retinoblastoma from 1914-1984. Data on these patients regarding the rates of soft-tissues sarcomas were compared to the general population.

The researchers concluded that patients diagnosed with hereditary retinoblastoma appear to have a significantly increased risk of developing soft-tissue sarcomas. This risk was increased in these patients whether or not they received radiation therapy and remained increased outside the field of radiation therapy; this indicates a potential genetic susceptibility for soft tissue sarcomas among patients with hereditary retinoblastoma.

St. Jude Children's Research Hospital scientists have demonstrated a new locally applied treatment for the eye cancer retinoblastoma. The new treatment, tested on mice, reduced the size of the tumor and also did not cause the side effects common with chemotherapy.

This targeted therapy uses a customized drug to disable a specific molecule inside a growing cancer cell. It is delivered locally to the site of the disease, rather than using systematic treatment. Dr. Dyer, Ph. D., associate member of the St. Jude Department of Developmental Neurobiology said "The findings suggest that this treatment not only could offer children with retinoblastoma more effective and less toxic treatment, it could also increase the chance that their vision can be preserved by eliminating the tumor and preventing its spread from the eye to the rest of the body".

Retinoblastoma occurs in about 5,000 young children worldwide each year, arising from the immature retina, which is the part of the eye responsible for detecting light and color. A report on this work appears in the November 2nd issue of the journal Nature.